AEROSPHERE^® Technology

AEROSPHERE next generation device delivery technology is offered in both TRIXEO (ICS/LABA/ LAMA) and BEVESPI (LABA/LAMA), providing pMDI device and molecular continuity to patients.^1,2

TRIXEO (ICS/LABA/LAMA)

Discover TRIXEO

BEVESPI (LAMA/LABA)

Discover BEVESPI

AEROSPHERE particles mechanism of action

AEROSPHERE technology is enabled by innovative, porous particles made of phospholipids, a major component of lung surfactant.^3-5 These particles are optimally sized at 1 to 2 micrometres, and deliver inhaled therapies throughout the lungs for COPD treatment.³

To find out more about AEROSPHERE technology, watch this video:^7-10,14

Their light foam nanostructure enhances aerodynamics and aerosolization and a corrugated surface allows drug crystals to attach to the particles in the right proportions for dose uniformity.³ The drug crystals remain attached to the surface after actuation, to ensure effective delivery throughout the lung.^3,5 This technology also reduces potential drug-drug interactions for multi-drug combinations within a single inhaler device.⁶

AEROSPHERE technology offers:^{3,4,6–11,14}

Effective, consistent delivery to the whole lung, both large and small airways
A stable homogenous suspension that delivers a consistent dose
Optimally sized vehicles for delivering inhaled drugs
Consistent deposition of drug combination in the airways
AEROSPHERE technology offers a lung deposition rate of 38% to 41%

More information on how to use the inhaler

logo

BEVESPI AEROSPHERE:

A LAMA/LABA that provides dual bronchodilation to the whole lung^9-14

BEVESPI AEROSPHERE is indicated as a maintenance bronchodilator treatment  to relieve symptoms in adult patients with COPD²

Outcomes from clinical trials

Improved lung function vs placebo (measured by morning pre-dose trough FEV₁ and peak FEV₁ over and at 24 weeks)^.2,12

ONSET OF ACTION¹²

At 5 minutes following administration of the first dose on day 1, there was significant improvement in FEV₁ from baseline vs placebo (in PINNACLE-1 and PINNACLE-2 studies respective differences were 187 and 186 mL, all p<0.0001)^2,12

INNOVATIVE AEROSPHERE DELIVERY TECHNOLOGY⁴

Aerosphere technology enables effective, consistent dose delivery to the whole lung with lung deposition of 38.4% with BEVESPI AEROSPHERE.^4¶

IMPROVEMENTS IN FEV₁^12,15*

BEVESPI AEROSPHERE demonstrated statistically significant improvements in trough FEV₁ at 24 weeks vs both monocomponents^12,13,15

QUALITY OF LIFE^2,12,15

Improvement of Health-related quality-of-life (SGRQ scores) with Bevespi was statistically but not clinically significant at Week 24 vs placebo in PINNACLE-1, PINNACLE-2, and PINNACLE-4 trials.^2,12‡

The most common adverse reactions reported in the clinical development program (comprised of 1,588 patients receiving Bevespi Aerosphere) were headache (1.9%), nausea (1.4%), muscle spasms (1.4%), and dizziness (1.3%).² The most common adverse reactions from the SmPC were anxiety, headache, dizziness, dry mouth, nausea, muscle spasms, urinary tract infection and chest pain.² Please refer to the SmPC for the full list of adverse events.²

*PINNACLE 1: 59 mL vs glycopyrrolate and 64 mL vs formoterol (both p<0.0001); PINNACLE 2: 54 mL vs glycopyrrolate (p<0.0003) and 56 mL vs formoterol (p<0.0002); PINNACLE 4: 59 mL vs glycopyrrolate and 72 mL vs formoterol (both p<0.0001).

‡Health-related quality of life was measured using the SGRQ. An improvement of 4 points in the SGRQ total score is the minimal clinically important difference.¹²

¶Based on a phase 1 trial of radiolabelled BEVESPI vs radiolabelled placebo pMDI (n=10). The dose detected in the oropharyngeal and stomach regions was 61% and 67% for BEVESPI and placebo, respectively.⁴

FEV₁, forced expiratory volume in first second; FRI, functional respiratory imaging; ICS, inhaled corticosteroid; LABA, long-acting beta2-agonist; LAMA, long-acting muscarinic antagonist; SGRQ, St George’s Respiratory Questionnaire, pMDI, pressurised metered dose inhaler; COPD, chronic obstructive pulmonary disease, n, number of patients

TRIXEO AEROSPHERE 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension. Summary of Product Characteristics.
BEVESPI AEROSPHERE 5 micrograms/7.2 micrograms pressurised inhalation, suspension. Summary of Product Characteristics.
Vehring R et al. Cosuspensions of microcrystals and engineered microparticles for uniform and efficient delivery of respiratory therapeutics from pressurized metered dose inhalers. Langmuir. 2012;28(42): 15015–15023. doi: 10.1021/la302281n.
Taylor G et al. Gamma scintigraphic pulmonary deposition study of glycopyrronium/formoterol metered dose inhaler formulated using co-suspension delivery technology. Eur J Pharm Sci. 2018;111: 450–457. doi: 10.1016/j.ejps.2017.10.026.
Fernandez-Tena A et al. Deposition of inhaled particles in the lungs. Arch Bronconeumol. 2012;48(7): 240–246. doi: 10.1016/j.arbres.2012.02.003.
Ferguson GT et al. Co-suspension delivery technology in pressurized metered-dose inhalers for multi-drug dosing in the treatment of respiratory diseases. Respir Med. 2018;134: 16–23. doi: 10.1016/j.rmed.2017.09.012.
De Backer LA et al. A randomized study using functional respiratory imaging to characterize bronchodilator effects of glycopyrrolate/formoterol fumarate delivered by a metered dose inhaler using co-suspension delivery technology in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2018;13: 2673–2684. doi: 10.2147/COPD.S171707.
Marshall J, et al. Poster presented at: ATS International Conference, May 19-24, 2023; Washington, DC. P406.
van den Berge M et al. Functional respiratory imaging assessment of budesonide/glycopyrrolate/formoterol fumarate and glycopyrrolate/formoterol fumarate metered dose inhalers in patients with COPD. Presented at the CHEST 2020 Virtual Congress, October 2020. P1456.
Usmani OS et al. Consistent Pulmonary Drug Delivery with Whole Lung Deposition Using the Aerosphere Inhaler: A Review of the Evidence. Int J Chron Obstruct Pulmon Dis. 2021 16:113-124. doi: 10.2147/COPD.S274846. PMID: 33500616; PMCID: PMC7822085.
Israel S et al. Pulmonary deposition of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler formulated using co-suspension delivery technology in healthy male subjects. Eur J Pharm Sci. 2020 153:105472. doi: 10.1016/j.ejps.2020.105472. Epub 2020 Jul 16. PMID: 32682074.
Martinez FJ et al. Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPD. Chest. 2017 151(2):340-357. doi: 10.1016/j.chest.2016.11.028. PMID: 27916620.
Reisner C et al. 24-h bronchodilation and inspiratory capacity improvements with glycopyrrolate/formoterol fumarate via co-suspension delivery technology in COPD. Respir Res. 2017 18(1):157. doi: 10.1186/s12931-017-0636-4. PMID: 28821260; PMCID: PMC5563048.
Usmani et al. Respiratory Research. 2023; 24:226
Lipworth BJ et al. Improved lung function and patient-reported outcomes with co-suspension delivery technology glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a randomized Phase III study conducted in Asia, Europe, and the USA. Int J Chron Obstruct Pulmon Dis. 2018 13:2969-2984. doi: 10.2147/COPD.S171835. PMID: 30310273; PMCID: PMC6167125.

GB-57038 | November 2024

TRIXEO and AEROSPHERE are registered trademarks of the AstraZeneca group of companies.

Welcome to this UK AstraZeneca produced and funded website

TRIXEO AEROSPHERE

AEROSPHERE® Technology

AEROSPHERE next generation device delivery technology is offered in both TRIXEO (ICS/LABA/ LAMA) and BEVESPI (LABA/LAMA), providing pMDI device and molecular continuity to patients.1,2

TRIXEO (ICS/LABA/LAMA)

BEVESPI (LAMA/LABA)

AEROSPHERE particles mechanism of action

AEROSPHERE technology offers:3,4,6–11,14

BEVESPI AEROSPHERE:

A LAMA/LABA that provides dual bronchodilation to the whole lung9-14

BEVESPI AEROSPHERE is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD2

Discover BEVESPI AEROSPHERE here

ONSET OF ACTION12

INNOVATIVE AEROSPHERE DELIVERY TECHNOLOGY4

IMPROVEMENTS IN FEV112,15*

QUALITY OF LIFE2,12,15

Abbreviations and References